ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2278 • ACR Convergence 2025

    Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study

    John Tesser1, Angela Crowley2, Jane Box3, Joshua June4, Pendleton Wickersham5, Guillermo Valenzuela6, Norman Gaylis7, Gordon Lam8, Leroy Pacheco9, David Ridley10, Gineth Pinto-Patarroyo11, Stuart Novack12, Melvin Churchill13, Minna Kohler14, Eric Lee15, Jose A Pando16, Glenn R. Parris17, Jeff Peterson18, Tina Shah19, Atul Singhal20, Victoria Vuong21, Jeffrey Curtis22 and David Chernoff23, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 3DJL Clinical Research, PLLC, Charlotte, NC, 4Great Lakes Center of Rheumatology, Lansing, MI, 5Arthritis Associates PA, San Antonio, TX, 6Integral Rheumatology & Immunology Specialists, Plantation, FL, 7Arthritis & Rheumatic Disease Specialties, Aventura, FL, 8Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, 9Albuquerque Ctr for Rheumatology, Albuquerque, NM, 10Saint Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Herndon, VA, 12Nuvance Health network, NORWALK, CT, 13Arthritis Center of Nebraska, Lincoln, NE, 14Massachusetts General Hospital, Harvard Medical School, Boston, MA, 15Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, 16Delaware Arthritis, Lewes, DE, 17PARRIS & ASSOCIATES, Lilburn, GA, 18Western Washington Arthritis Clinic, Seattle, WA, 19Kansas City Physician Partners, Kansas City, MO, 20SouthWest Arthritis Research Group, Mesquite, TX, 21Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, 22University of Alabama at Birmingham, Birmingham, AL, 23SetPoint Medical, Sausalito, CA

    Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
  • Abstract Number: 1976 • ACR Convergence 2025

    Implementing a Change Package for Depression Screening and Appropriate Response for Children with Rheumatic Disease

    Emily Vara1, Mileka Gilbert1, Kelly Rouster-Stevens2, Talia Buitrago-Mogollon3, Sarah Mabus3, Justin Moore4 and Sheetal Vora5, 1Medical University of South Carolina, Charleston, SC, 2Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, 3Atrium Health Levine Children’s Center for Advancing Pediatric Excellence, Charlotte, NC, 4Wake Forest School of Medicine, Winston Salem, NC, 5Atrium Health Levine Children's Hospital, Charlotte, NC

    Background/Purpose: Children with rheumatic diseases (RD) are at increased risk for developing mental health (MH) issues, including depression, which can negatively impact disease outcomes. MH…
  • Abstract Number: 1517 • ACR Convergence 2025

    The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters

    Aijing Liu1, Fei Chang2 and Qiuhong Xu1, 1Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), 2Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)

    Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
  • Abstract Number: 1278 • ACR Convergence 2025

    Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus

    Emily Masi1, Kimberly Rapoza2, Tamar Rubinstein3, Kathy Kenney-Riley4 and Joyce Hui-Yuen5, 1Cohen Children's Medical Center, North New Hyde Park, NY, 2Mercy College, Dobbs Ferry, NY, 3Albert Einstein College of Medicine, White Plains, NY, 4Mercy University, Dobbs Ferry, NY, 5North Shore LIJ Health System, Great Neck, NY

    Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
  • Abstract Number: 0721 • ACR Convergence 2025

    Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Mats Junek1, Sara Choi2, Stephanie Garner3, Saara Rawn4, David Cuthbertson5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Philip Seo12, Ulrich Specks13, Kenneth Warrington13, Gerard Cox1, Nader Khalidi14 and Peter Merkel8, 1St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 2Queen's University, Kingston, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4NOSM School of Medicine, Sudbury, ON, Canada, 5University of South Florida, Tampa, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD, 13Mayo Clinic, Rochester, MN, 14McMaster University, Hamilton, ON, Canada

    Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
  • Abstract Number: 0545 • ACR Convergence 2025

    Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis

    Omar-Javier Calixto1, Uta Kiltz2, Brikena Lalazi3, Franziska Neinert3, Philipp Sewerin4 and Xenofon Baraliakos2, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Herne, Nordrhein-Westfalen, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany

    Background/Purpose: The phenotypes of axial spondyloarthritis (axSpA) and clinical responses to placebo and study drugs in randomized controlled trials (RCTs) have changed over time. We…
  • Abstract Number: 0325 • ACR Convergence 2025

    Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)

    C. Kent Kwoh1, Amanda Nelson2, Rongrong Tang3, Edward J. Bedrick3, Yong Ge1, Yvonne Golightly4, Zong-Ming Li3, Jean Liew5, Xiaoxiao Sun1, Jeffrey Duryea6 and Tuhina Neogi5, 1The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3The University of Arizona Arthritis Center, University of Arizona, Tucson, 4University of Nebraska Medical Center, Omaha, NE, 5Boston University School of Medicine, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…
  • Abstract Number: 2387 • ACR Convergence 2025

    Lupus Damage Index Revision – Item Generation and Reduction Phases

    Burak Kundakci1, Megan Barber2, Ann Clarke2, Sindhu Johnson3 and Ian Bruce4, 1Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom

    Background/Purpose: The current Systemic Lupus Erythematosus Damage Index (SDI) is a robust instrument, but is limited by missing items, restricted applicability in pediatric patients, and…
  • Abstract Number: 2276 • ACR Convergence 2025

    Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data

    Jennifer Hanberg1, David Cheng2, Xuan Wang3, Rahul Sangar4, Yuk-Lam Ho4, Lauren Costa4, Rachael Matty4, Candace Feldman1, Tate Johnson5, Joshua Baker6, Bryant England5, J. Michael Gaziano1, Kelly Cho7, James O'Dell5, Grant Cannon8, Paul Monach4, Ted Mikuls5, Tianxi Cai7 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3University of Utah, Salt Lake City, UT, 4VA Boston Healthcare System, Boston, MA, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania, Philadelphia, PA, 7Harvard Medical School, Boston, MA, 8University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
  • Abstract Number: 1972 • ACR Convergence 2025

    Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic

    Abimbola Fadairo-Azinge1, jobelle Romulo2, Daniella Flores3, jose Giron2, Joshua Ng4, Sarah Patterson5, Jinoos Yazdany6 and Andrew Gross6, 1UCSF, San Francisco, 2University of California San Francisco, San Francisco, 3University of California San Francisco, San Francisco, CA, 4University of California San Francisco, SAN-FRANCISCO, CA, 5University of California, San Francisco, Pacifica, CA, 6UCSF, San Francisco, CA

    Background/Purpose: The American College of Rheumatology (ACR) recommends contraceptive counseling for reproductive-age women with rheumatic and musculoskeletal diseases (RMDs), especially those on teratogenic medications. These…
  • Abstract Number: 1493 • ACR Convergence 2025

    Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods

    Lilliana Serrano-Arroyo, César Rosado-Bloise and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR

    Background/Purpose: The post-acute sequelae of SARS-CoV-2 infection may involve low-grade inflammation, immune dysregulation, and endothelial dysfunction. Therefore, it would not be surprising if SARS-CoV-2 negatively…
  • Abstract Number: 1255 • ACR Convergence 2025

    Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience

    Reena Yaman1, Lisa Balistreri2, Maximiliano Diaz Menindez3, Sehreen Mumtaz1, Megan Sullivan3, Alexander Hochwald1 and Florentina Berianu1, 1Mayo Clinic Florida, Jacksonville, FL, 2Lee Health, Cape Coral, FL, 3Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
  • Abstract Number: 0691 • ACR Convergence 2025

    Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis

    Brian Lee1, Shufeng Li1, Srijana Davuluri2, Jennifer Lee1 and Lorinda Chung2, 1Stanford University, Stanford, 2Stanford University, Stanford, CA

    Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
  • Abstract Number: 0539 • ACR Convergence 2025

    Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort

    Liese de Bruin1, Floris A. van Gaalen1, Manouk de Hooge2, Miranda van Lunteren1, Mary Lucy Marques3, Monique Reijnierse4, Roberta Ramonda5, Inger Jorid Berg6, Sofia Exarchou7, Robert Landewé8, Désirée Van Der Heijde1 and Sofia Ramiro9, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 4Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, 66Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, 7Lund University, Åkarp, Skane Lan, Sweden, 8Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 9Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The assessment of structural damage progression is an important part of outcome assessment in axial SpA (axSpA). In order to test whether interventions can…
  • Abstract Number: 0313 • ACR Convergence 2025

    People with Knee Osteoarthritis Infrequently Seek Medical Care for Arthritis, Even Those With Severe Disease

    Grace Lo1, Shunshun Yan2, Julieann Patarini3, Timothy McAlindon4, Charles Eaton5 and Jeffrey Driban6, 1Baylor College of Medicine / MEDVAMC, Houston, TX, 2Baylor College of Medicine, Houston, 3UMass Chan Medical School, Worcester, MA, 4UMass Chan School of Medicine, Arlington, MA, 5Brown University, Providence, RI, 6University of Massachusetts Chan Medical School, Marlborough, NH

    Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, a condition associated with substantial disability. Providers are often uncomfortable managing arthritis, and patients with…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 59
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology